Skip to Main Content

After years of litigation, Bristol Myers Squibb (BMY) agreed to pay $75 million, plus interest, to resolve allegations of knowingly underpaying rebates that were owed to state Medicaid programs.

The settlement, which the company had signaled a year ago was in the works, stems from a whistleblower lawsuit filed in 2013 by the former head of a health care industry trade group who had filed similar suits against several drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED